Rabin Medical Center News


News from Rabin Medical Center – Obesity in Adolescence Linked With Subsequent Colorectal Cancer

Overweight and obesity in adolescence were associated with an increased risk for colon cancer later in life among both men and women, according to the results of a recent study. Obesity, but not overweight, was also linked to subsequent rectal cancer.

Researchers were extending previous work looking at the association between body mass index (BMI) measured at adolescence and risk for colorectal cancer (CRC) among men. The study was expanded to include women and by updating the cancer registry linkage data to increase the number of CRC cases.

“The association between adolescent BMI and CRC among men has been addressed in several studies, some reporting little or no association, a possible association, or a positive association,” wrote Zohar Levi, MD, of the Rabin Medical Center, Tikva, Israel, and colleagues.

According to the researchers, few previous studies have reported on colon and rectal cancers separately.

“Our data indicate that the risk for rectal cancer may be increased only for obese adolescents, and this suggests possibly different mechanisms for colon cancer and rectal cancer,” the researchers wrote. “This might be supported by reports of a differential impact of obesity on the risk of adenomas and may provide some explanation for the inconsistencies concerning the association of BMI with rectal cancer in women reported in several studies.”

Source: http://www.cancernetwork.com/colorectal-cancer/obesity-adolescence-linked-subsequent-colorectal-cancer


Israel Sends Aid To Flood-Battered Texas


Humanitarian aid organizations IsraAID and iAID send teams to help clear debris, clean ruined homes and offer psychological support to Harvey survivors.

Two teams of Israeli aid experts are on their way to Texas to provide vital relief and psychosocial support to the thousands of people who have lost everything in the catastrophic Tropical Storm Harvey.

The storm, which first hit Texas on Sunday and continues to plague the beleaguered state with pounding rain, has left nine dead, and tens of thousands of people homeless as flood waters have poured through city streets in Houston, the fourth-largest city in the United States. The storm is thought to have affected 6.8 million people in 18 countries, a quarter of the Texas population.

Humanitarian aid organization IsraAID aims to provide a two-stage response to the disaster, focusing on helping remove debris and clean homes in the wake of the catastrophic flooding, and offering psychosocial trauma support to shocked residents.

“In crises with large-scale destruction, national and international aid efforts typically focus on practical, physical support, with limited resources allocated to the mental and emotional rehabilitation of affected populations,” said Yotam Polizer, co-CEO of IsraAID.

iAID, an international aid organization based in Israel, is also sending a team of 9-10 Israeli relief professionals to offer support to the national guard and other non-governmental American aid groups, to help families and communities affected by the storm.

IsraAID, which is working closely with Jewish communities, the local government in Texas, and the Israeli Consul General, plans to deploy 5-7 experts from both Israel and the US, to offer psychological support to vulnerable population groups evacuated to shelters in Austin and Dallas.

They will create and facilitate child-friendly spaces within the shelters to help support homeless children, and offer psychological and emotional support and tools for both individuals and for community resilience-building.

The organization will also send a relief team to help local communities remove debris, clean out destroyed homes and help residents sift through the wreckage of former homes to salvage belongings.

IsraAID announced it will prioritize those who do not have insurance or the financial means to clear the debris, and those who are unable to clean up their homes for other reasons.

IsraAID has also sent disaster relief to the US following floods in Louisiana, the Carolinas, Denver and Detroit, hurricanes in Oklahoma, New York and New Orleans, and wildfires in Washington.


Coming of age, Israel biotech sector gets ready for market

The sale of Israeli drugmaker NeuroDerm to Japanese pharma giant Mitsubishi Tanabe for $1.1 billion last month in the largest ever purchase of an Israeli healthcare company, has put the spotlight on Israel’s biotech sector, where a number of other firms are gearing up for commercialization of their product.


NeuroDerm develops treatments for patients suffering from Parkinson’s disease, as well as other disorders related to the central nervous system.

The firm’s leading product candidate is not even on the market yet, but is in advanced clinical trials in both Europe and the United States. The product could hit the market as early as 2019.

The NeuroDerm deal, Anna Eldan of Israel Innovation Startup Authority said, “is the beginning of the coming of age of the Israeli biotech industry, and it is the result of a long-term government policy. We are very happy to see this kind o maturation, and there is still a lot of work to do.”

But, she added, “eventually out of these young innovative companies the next big Israeli pharma firm will emerge.”

“We are at an exciting transition point, and moving from being a research and development firm, based in Israel, to an international commercial firm,” Gamida Cell’s CEO Yael Margolin, who has headed the privately held company for the past 12 years, said in an interview earlier this month. Pharma giant Novartis is one of the investors in the firm.

As shown in the IATI report, over the last decade, Israeli life sciences companies have raised more than $6.7 billion on NASDAQ exchange, with $5 billion raised since 2013. The Nasdaq remains the main source for public offerings for Israeli life sciences companies, with more public offerings and more money raised than on all other exchanges combined, including on the Tel Aviv Stock Exchange (TASE).

The shares of 60 life sciences firms are listed on TASE, the report said, of which 21, like BiondVax and RedHill, are dual-listed on foreign markets. These include biotechnology firms, holding companies that invest in life sciences technologies and firms, medical device companies and pharma companies.

The Israeli government continues to focus on providing a support network for R&D through various programs providing grants and other incentives, the IATI report said.


Source: http://www.timesofisrael.com/coming-of-age-israel-biotech-sector-gets-ready-for-market/?utm_source=Start-Up+Daily&utm_campaign=134b9a1a0b-EMAIL_CAMPAIGN_2017_08_17&utm_medium=email&utm_term=0_fb879fad58-134b9a1a0b-55366073

New Breast Cancer Treatment Options


New breast cancer blood test could improve treatment options in more serious cases

‘Liquid biopsy’ detects tumor DNA and can track alterations in 13 different genes.


Women with advanced stages of breast cancer could receive potentially life-extending personalized treatment after taking a new blood test that detects tumor DNA.

The test, known as a “liquid biopsy”, can detect and track alterations in 13 different genes, including some of the most important drivers of the disease.

For patients whose cancer has spread beyond the breast and nearby glands – the most deadly stage of the disease – the new test could be used to improve and individualize their treatment as the disease progresses, researchers have said.

Around 10 percent of women have metastatic, or stage four, breast cancer at the time of their diagnosis, according to cancer support charity Macmillan. The average survival rate is around two years.

This is the first time scientists have been able to analyze two kinds of acquired DNA mutation in a single blood test. In addition, the test can spot mutations in the estrogen receptor gene ESR1, linked to resistance to anti-hormone therapies such as aromatase inhibitors.

“This study represents proof of concept, and further validation is now needed to confirm the clinical usefulness of this test before any test could be rolled out…The researchers may have developed a way to track breast cancer as it grows, allowing doctors to act swiftly and give patients the treatments that are right for them as early as possible. On top of that, such a tailored approach could spare patients receiving drugs, and the side effects that go with them, that aren’t likely to work.”

Source: http://www.independent.co.uk/news/health/breast-cancer-blood-test-new-treatment-improve-detect-tumour-dna-liverpool-uk-advanced-metastatic-a7862241.html

Tumor Test Helps Identify Which Breast Cancers Don’t Require Extra Treatment


Tumor Test Helps Identify Which Breast Cancers Don’t Require Extra Treatment

For years, doctors have focused on detecting breast cancer at the earliest possible moment after a tumor develops so treatment can start right away. But more and more studies are showing many small, early tumors don’t present a danger.

So, when is it safe to remove a tumor but skip additional treatments like tamoxifen, chemotherapy and radiation?

study published Thursday in JAMA Oncology suggests that it may be possible to distinguish fairly precisely between “ultra low-risk” tumors that are unlikely to cause problems and those that are more aggressive and likely to spread — thus allowing some patients to avoid unnecessary treatments.

Researchers in the U.S. and Sweden used a diagnostic test called MammaPrint to measure a tumor’s genomic “fingerprint” and compared it with survival time after a tumor was removed. They say they were able to pinpoint patients who had a very low risk of death from breast cancer — even up to 20 years after the first diagnosis.

MammaPrint is a genomic test that looks at a set of 70 genes in a tumor, showing how the genes are controlling the production of the proteins that drive a tumor’s growth. A genomic test of the tumor, which measures how genes are functioning, differs from other genetic tests that determine someone’s hereditary risk of cancer.

The tumor test was approved by the Food and Drug Administration in 2007 to predict whether an existing cancer has the ability to spread. It’s priced at $4,200 and is covered by some insurance plans in the U.S.


Source: http://n.pr/2s6VO4v

Effective Immunotherapy Steps Closer With New T Cell Study


Effective Immunotherapy Steps Closer With New T Cell Study 

In a recent study, researchers report some progress in developing an immunotherapy for ovarian cancer. However, they also outline the considerable challenges that remain before the treatment can be made effective for this and other cancers that have solid tumors.

The researchers presented the findings at the annual meeting of the American Association of Cancer Research in Washington, D.C. Estimates from the American Cancer Society  suggest that, in the United States, around 22,440 women will be diagnosed with ovarian cancer and approximately 14,000 will die from the disease during 2017.

The cancer begins in cells of the ovaries – reproductive glands found only in women. Each woman normally has two ovaries, situated on each side of the uterus inside the pelvis. The ovaries produce eggs that travel to the uterus through the fallopian tubes.

Dr. Kristin Anderson, an immunotherapy researcher who presented the findings at the meeting, says that while ovarian cancer is not as common in the U.S. as other cancers with solid tumors, it has a low rate of survival and a high rate of relapse. The main reason is that the cancer does not cause obvious symptoms and is often advanced by the time it is diagnosed.

Immunotherapy is a relatively new area of medicine that is showing promising results in the treatment of cancer. The approach uses the patient’s own immune system to fight disease.

The new study concerns a method called adoptive T cell transfer. In this approach, immune cells called T cells are taken from the patient’s own blood and trained to target and destroy cancer cells. Then, after multiplying in the laboratory, the primed cells are returned to the patient’s body. Sometimes donor cells are used instead.

The team hopes to start a human clinical trial of adoptive T cell transfer for ovarian cancer in the next few years.

My Breast Cancer Story by Rebecca Guenther


In March of 2013 after a routine mammogram I received a diagnosis of breast cancer. After discovering that I was a carrier of the BRCA2 mutation I had a bilateral mastectomy in April, breast reconstruction and ovarian removal in May. Fortunately, the cancer was small, only in one breast, and hadn’t spread to the lymph nodes, so I didn’t have to undergo chemotherapy. The reconstruction was difficult and long, but I recuperated fairly quickly from the multiple surgeries (probably due to my high level of fitness as a runner). I celebrated my recovery by running the New York City Marathon on Nov. 3, 2013, between stages of breast reconstruction. I raised about $5,000 for the Dublin Breast Center at Mount Sinai Hospital.

Running the marathon was a way for me to say to breast cancer that I would fight it and not let it get me, and it gave me a sense of control over my body. It made me constantly reflect on my mortality and the lack of control over my body, even though I’ve done everything I could to be fit and healthy my entire adult life. I’ve been a runner since the late 1970s, when I was in my 20s, and have always eaten a healthy, low-fat diet. During the marathon, I felt strong and determined. When I ran up 5th Ave by Mount Sinai Hospital where I had been treated I was overcome by emotion.

A few days after the 2013 marathon I had the tissue extenders replaced with implants, which involved another recovery period. After that I continued to run, improving my times until in late September of 2015 my son, then age 34, suddenly died of a burst ulcer while he was living in Peru. The overwhelming grief and anxiety affected my running and stamina and I realized the strong connection between emotional and physical health. While experiencing chest pain (that ultimately was determined to be related to the grief), I found out that I had yet another hereditary condition—a high percentage of Lipoprotein-A, which is a particle in the blood that carries cholesterol, fats and proteins, causing a build-up of fatty deposits in the arteries and thus an increased risk for heart attack and stroke. It isn’t affected by diet and exercise– another thing that gave me less control over my body. Shortly before my son’s death, my then 29-year old daughter tested positive for the BRCA2 mutation, which is a source of anxiety for both of us.

We never know what the next big test in life will be, and many things are out of our control—but knowing that people are willing to make sacrifices to help combat cancer and other diseases can give us some comfort.